BR112017003462A2 - coronavírus bovino atenuado, vacina, e, método de vacinação de um bovino. - Google Patents

coronavírus bovino atenuado, vacina, e, método de vacinação de um bovino.

Info

Publication number
BR112017003462A2
BR112017003462A2 BR112017003462A BR112017003462A BR112017003462A2 BR 112017003462 A2 BR112017003462 A2 BR 112017003462A2 BR 112017003462 A BR112017003462 A BR 112017003462A BR 112017003462 A BR112017003462 A BR 112017003462A BR 112017003462 A2 BR112017003462 A2 BR 112017003462A2
Authority
BR
Brazil
Prior art keywords
bovine
vaccines
vaccination
vaccine
coronavirus
Prior art date
Application number
BR112017003462A
Other languages
English (en)
Other versions
BR112017003462B1 (pt
Inventor
M Peters Catherine
Trigo Emilio
W Mellencamp Mark
Lee Wasmoen Terri
Xue Wenzhi
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of BR112017003462A2 publication Critical patent/BR112017003462A2/pt
Publication of BR112017003462B1 publication Critical patent/BR112017003462B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20061—Methods of inactivation or attenuation
    • C12N2770/20064—Methods of inactivation or attenuation by serial passage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

a presente invenção descreve novos isolados de coronavírus bovino atenuado, composições compreendendo esses isolados, e métodos de uso de tais composições em vacinas, incluindo em vacinas vivas. a presente invenção descreve adicionalmente a administração de tais vacinas, incluindo a administração intranasal de tais vacinas, para auxiliar na prevenção de doença respiratória causada por coronavírus bovino.
BR112017003462-0A 2014-09-03 2015-09-02 Coronavírus bovino atenuado e vacina BR112017003462B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462045183P 2014-09-03 2014-09-03
US62/045,183 2014-09-03
US201462073263P 2014-10-31 2014-10-31
US62/073,263 2014-10-31
PCT/EP2015/070006 WO2016034610A1 (en) 2014-09-03 2015-09-02 Attenuated bovine coronavirus and related vaccines

Publications (2)

Publication Number Publication Date
BR112017003462A2 true BR112017003462A2 (pt) 2017-12-05
BR112017003462B1 BR112017003462B1 (pt) 2023-02-14

Family

ID=54012224

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017003462-0A BR112017003462B1 (pt) 2014-09-03 2015-09-02 Coronavírus bovino atenuado e vacina

Country Status (9)

Country Link
US (1) US10434168B2 (pt)
EP (1) EP3188750B1 (pt)
AU (1) AU2015310932B2 (pt)
BR (1) BR112017003462B1 (pt)
CA (1) CA2957472C (pt)
ES (1) ES2788393T3 (pt)
HU (1) HUE049826T2 (pt)
MX (1) MX2017002803A (pt)
WO (1) WO2016034610A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2694499C1 (ru) * 2018-01-16 2019-07-15 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кубанский государственный аграрный университет имени И.Т. Трубилина" Тест-система для обнаружения генома возбудителя коронавирусной инфекции у крупного рогатого скота с помощью мультиплексной полимеразной цепной реакции с флуоресцентной детекцией в режиме реального времени
RU2694558C1 (ru) * 2018-01-16 2019-07-16 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кубанский государственный аграрный университет имени И.Т. Трубилина" Способ выявления генома возбудителя коронавирусной инфекции у крупного рогатого скота
KR102089655B1 (ko) * 2018-08-17 2020-03-16 전남대학교 산학협력단 소 코로나바이러스 감염증 예방용 kwd20v-102 주의 약독화 생백신 조성물
US11419876B2 (en) 2019-09-06 2022-08-23 Iowa State University Research Foundation, Inc. Mirtazapine as a pre-shipping inhibitor of bovine respiratory disease
RU2740097C1 (ru) * 2020-08-11 2021-01-11 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кубанский государственный аграрный университет имени И.Т. Трубилина" Способ выявления генома возбудителя коронавирусной инфекции нового типа (nCov19) у приматов
RU2741887C1 (ru) * 2020-08-11 2021-01-29 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кубанский государственный аграрный университет имени И.Т. Трубилина" Тест-система для выявления генома возбудителя коронавирусной инфекции нового типа (nCov19) у приматов
CN117157310A (zh) * 2021-01-14 2023-12-01 拉斐尔·保罗·维西迪 针对高致病性冠状病毒的溶细胞性t细胞免疫疗法
WO2023038961A2 (en) * 2021-09-08 2023-03-16 La Jolla Institute For Immunology Common cold coronavirus t cell epitopes, methods and uses thereof
CN116559439A (zh) * 2023-04-24 2023-08-08 江苏省农业科学院 一种牛冠状病毒间接elisa抗体检测试剂盒及应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3873422A (en) * 1972-10-30 1975-03-25 Univ Nebraska Vaccine for neonatal calf diarrhea
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
DE69835424T2 (de) * 1997-03-10 2007-02-08 Immtech Biologics, LLC, Bucyrus Boviner atmungs- und darmcoronavirus als impfstoff
NZ514103A (en) 1997-09-25 2001-09-28 Biotechnology Res & Dev LktA deletion mutant of P. haemolytica
US6974577B2 (en) 2001-02-04 2005-12-13 Novartris Ag Inactivated bovine scours vaccines, processes and method of preventing bovine scours
PT1638598E (pt) 2003-07-02 2007-03-30 Biotechnology Res & Dev Mutantes acapsulares de deleção de hyae de p. multocida
EP1533370A1 (en) * 2003-11-18 2005-05-25 ViroNovative B.V. Novel atypical pneumonia-causing virus
US8440203B2 (en) * 2009-11-06 2013-05-14 Intervet Inc. Methods of immunizing pregnant heifers at three months of gestation
DK3106176T3 (en) * 2011-12-06 2018-01-08 Valneva Austria Gmbh ALUMINUM COMPOUNDS FOR USE IN THERAPEUTICS AND VACCINES
US9480739B2 (en) 2013-03-15 2016-11-01 Intervet Inc. Bovine virus vaccines that are liquid stable
US9393298B2 (en) 2013-03-15 2016-07-19 Intervet Inc. Liquid stable bovine virus vaccines

Also Published As

Publication number Publication date
US20170274065A1 (en) 2017-09-28
WO2016034610A1 (en) 2016-03-10
AU2015310932B2 (en) 2018-11-22
ES2788393T3 (es) 2020-10-21
CA2957472A1 (en) 2016-03-10
CA2957472C (en) 2021-10-26
EP3188750B1 (en) 2020-03-11
US10434168B2 (en) 2019-10-08
HUE049826T2 (hu) 2020-10-28
AU2015310932A1 (en) 2017-03-09
EP3188750A1 (en) 2017-07-12
BR112017003462B1 (pt) 2023-02-14
MX2017002803A (es) 2017-06-09

Similar Documents

Publication Publication Date Title
BR112017003462A2 (pt) coronavírus bovino atenuado, vacina, e, método de vacinação de um bovino.
CL2018001053A1 (es) Vacuna contra el virus sincicial respiratorio
CL2018001056A1 (es) Vacuna contra el virus herpes simplex
MX2022006603A (es) Vacuna contra el virus de la influenza de amplio espectro.
MD3718565T2 (ro) Vaccinuri împotriva virusului respirator
BR112018013387A2 (pt) vetor de vacinação recombinante, vírus mva, vacina ou composição farmacêutica e kit
MX2017001406A (es) Agentes a base de flagelina y usos de los mismos, incluyendo vacunación efectiva.
BR112017001310A2 (pt) coronavírus
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
MX2021010060A (es) Produccion de virus en huevos aviares.
PH12017500304A1 (en) Vaccine compositions against dengue virus diseases
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
MX2016016746A (es) Composiciones de vacuna con adyuvante dual, preparacion y usos.
MY191539A (en) Streptococcal vaccine
NZ731659A (en) Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
BR112019003992A2 (pt) vacina contra neisseria meningitidis
MX2017016896A (es) Vacunas inactivadas contra la influenza canina, metodos para elaborarlas y sus usos.
MX2019005102A (es) Poxvirus quimericos sinteticos.
MX2018014955A (es) Vacunas atenuadas vivas del virus de la influenza equina.
BR112016030728A2 (pt) método para tratar ou prevenir uma inflamação induzida por bactérias em um indivíduo, composição imunogênica, composição farmacêutica, uso da composição imunogênica, método para produzir uma composição imunogênica, e, método para tratar ou prevenir uma doença
PE20190225A1 (es) Un metodo para reducir la contaminacion de huevo
MX2018003173A (es) Vacunas de salmonella choleraesuis-salmonella typhimurium.
BR112017028052A2 (pt) peptídeo, método para induzir uma resposta imune em um sujeito e formulação de vacina
UY35077A (es) Formulaciones farmacéuticas y proceso de producción de formulaciones farmacéuticas
AR106464A1 (es) Vacuna de virus sincitial respiratorio

Legal Events

Date Code Title Description
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/09/2015, OBSERVADAS AS CONDICOES LEGAIS